Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jun 25;199:114973. doi: 10.1016/j.addr.2023.114973

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Elsevier B.V. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Fig. 5 — PHTA polymer-based mRNA cancer vaccine delivery system. (A) Synthetic scheme and preparation process of PHTA-Cn/mRNA nanovaccine. PHTA-Cn (n = 8, 10, 12, 14, 16, and 18) polymers were prepared via amino-epoxy polymerization. (B) Agarose gel electrophoresis images of PHTA-Cn/mRNA nanovaccine. (C) Therapeutic schedule of B16-OVA tumor-bearing mice using PHTA-C18/mRNA nanovaccine. (D) Tumor growth of PBS-, PHTA-C8/mRNA nanovaccine-, and PHTA-C18/mRNA nanovaccine-treated groups (n = 5 per group). (E) Tumor growth efficiency at the endpoint, compared with the PBS group (n = 5 per group). (F) Schematic illustration of therapeutic mechanism. Percentages of cells in B16-OVA tumor tissues on day 20: (G) CD4⁺ T-cells, and (H) CD8⁺ T-cells (n = 5 per group). Adapted with permission from reference [185].